Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Journal Sections
    • Subscriptions
    • Reviewing
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Collections
      • COVID-19 & Cancer Resource Center
      • Clinical Trials
      • Immuno-oncology
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
    • Journal Press Releases
  • COVID-19
  • Webinars
  • 10th Anniversary
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Discovery
Cancer Discovery
  • Home
  • About
    • The Journal
    • AACR Journals
    • Journal Sections
    • Subscriptions
    • Reviewing
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Collections
      • COVID-19 & Cancer Resource Center
      • Clinical Trials
      • Immuno-oncology
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
    • Journal Press Releases
  • COVID-19
  • Webinars
  • 10th Anniversary
  • Search More

    Advanced Search

Review

Fibroblast Growth Factor Receptor Inhibitors as a Cancer Treatment: From a Biologic Rationale to Medical Perspectives

Maria Vittoria Dieci, Monica Arnedos, Fabrice Andre and Jean Charles Soria
Maria Vittoria Dieci
1Breast Cancer Unit and 2Early Drug Development Unit (SITEP), Department of Medical Oncology; 3INSERM Unit U981, Gustave Roussy Institute, Villejuif; 4Paris Sud University, Orsay, France; and 5Department of Oncology, Hematology, and Respiratory Diseases, University Hospital, Modena, Italy
1Breast Cancer Unit and 2Early Drug Development Unit (SITEP), Department of Medical Oncology; 3INSERM Unit U981, Gustave Roussy Institute, Villejuif; 4Paris Sud University, Orsay, France; and 5Department of Oncology, Hematology, and Respiratory Diseases, University Hospital, Modena, Italy
1Breast Cancer Unit and 2Early Drug Development Unit (SITEP), Department of Medical Oncology; 3INSERM Unit U981, Gustave Roussy Institute, Villejuif; 4Paris Sud University, Orsay, France; and 5Department of Oncology, Hematology, and Respiratory Diseases, University Hospital, Modena, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Monica Arnedos
1Breast Cancer Unit and 2Early Drug Development Unit (SITEP), Department of Medical Oncology; 3INSERM Unit U981, Gustave Roussy Institute, Villejuif; 4Paris Sud University, Orsay, France; and 5Department of Oncology, Hematology, and Respiratory Diseases, University Hospital, Modena, Italy
1Breast Cancer Unit and 2Early Drug Development Unit (SITEP), Department of Medical Oncology; 3INSERM Unit U981, Gustave Roussy Institute, Villejuif; 4Paris Sud University, Orsay, France; and 5Department of Oncology, Hematology, and Respiratory Diseases, University Hospital, Modena, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Fabrice Andre
1Breast Cancer Unit and 2Early Drug Development Unit (SITEP), Department of Medical Oncology; 3INSERM Unit U981, Gustave Roussy Institute, Villejuif; 4Paris Sud University, Orsay, France; and 5Department of Oncology, Hematology, and Respiratory Diseases, University Hospital, Modena, Italy
1Breast Cancer Unit and 2Early Drug Development Unit (SITEP), Department of Medical Oncology; 3INSERM Unit U981, Gustave Roussy Institute, Villejuif; 4Paris Sud University, Orsay, France; and 5Department of Oncology, Hematology, and Respiratory Diseases, University Hospital, Modena, Italy
1Breast Cancer Unit and 2Early Drug Development Unit (SITEP), Department of Medical Oncology; 3INSERM Unit U981, Gustave Roussy Institute, Villejuif; 4Paris Sud University, Orsay, France; and 5Department of Oncology, Hematology, and Respiratory Diseases, University Hospital, Modena, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jean Charles Soria
1Breast Cancer Unit and 2Early Drug Development Unit (SITEP), Department of Medical Oncology; 3INSERM Unit U981, Gustave Roussy Institute, Villejuif; 4Paris Sud University, Orsay, France; and 5Department of Oncology, Hematology, and Respiratory Diseases, University Hospital, Modena, Italy
1Breast Cancer Unit and 2Early Drug Development Unit (SITEP), Department of Medical Oncology; 3INSERM Unit U981, Gustave Roussy Institute, Villejuif; 4Paris Sud University, Orsay, France; and 5Department of Oncology, Hematology, and Respiratory Diseases, University Hospital, Modena, Italy
1Breast Cancer Unit and 2Early Drug Development Unit (SITEP), Department of Medical Oncology; 3INSERM Unit U981, Gustave Roussy Institute, Villejuif; 4Paris Sud University, Orsay, France; and 5Department of Oncology, Hematology, and Respiratory Diseases, University Hospital, Modena, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/2159-8290.CD-12-0362 Published March 2013
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Online Impact

Statistics from Altmetric.com

ARTICLE USAGE

ARTICLE USAGE: February 2013 to January 2021

AbstractFull-text HTMLPDF
Total777573056806

Cited By

Article Information

Volume 3, Issue 3, pp. 264-279

DOI 
https://doi.org/10.1158/2159-8290.CD-12-0362
PubMed 
23418312

Published By 
American Association for Cancer Research
Print ISSN 
2159-8274
Online ISSN 
2159-8290
History 
  • Received August 1, 2012
  • Revision received November 27, 2012
  • Accepted November 30, 2012
  • Published first February 15, 2013.

Article Versions

  • Previous version (February 15, 2013 - 06:30).
  • You are viewing the most recent version of this article.
Copyright & Usage 
©2012 American Association for Cancer Research.

Author Information

  1. Maria Vittoria Dieci1,3,5,
  2. Monica Arnedos1,3,
  3. Fabrice Andre1,3,4 and
  4. Jean Charles Soria2,3,4
  1. Authors' Affiliations:1Breast Cancer Unit and 2Early Drug Development Unit (SITEP), Department of Medical Oncology; 3INSERM Unit U981, Gustave Roussy Institute, Villejuif; 4Paris Sud University, Orsay, France; and 5Department of Oncology, Hematology, and Respiratory Diseases, University Hospital, Modena, Italy
  1. Corresponding Author:
    Fabrice Andre, Comité 050, Gustave Roussy Institute, 114 rue E Vaillant, 94800 Villejuif, France. Phone: 003-314-211-4371; Fax: 003-314-211-5274; E-mail: fandre{at}igr.fr
View Full Text
PreviousNext
Back to top
Cancer Discovery: 3 (3)
March 2013
Volume 3, Issue 3
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Discovery article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Fibroblast Growth Factor Receptor Inhibitors as a Cancer Treatment: From a Biologic Rationale to Medical Perspectives
(Your Name) has forwarded a page to you from Cancer Discovery
(Your Name) thought you would be interested in this article in Cancer Discovery.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Fibroblast Growth Factor Receptor Inhibitors as a Cancer Treatment: From a Biologic Rationale to Medical Perspectives
Maria Vittoria Dieci, Monica Arnedos, Fabrice Andre and Jean Charles Soria
Cancer Discov March 1 2013 (3) (3) 264-279; DOI: 10.1158/2159-8290.CD-12-0362

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Fibroblast Growth Factor Receptor Inhibitors as a Cancer Treatment: From a Biologic Rationale to Medical Perspectives
Maria Vittoria Dieci, Monica Arnedos, Fabrice Andre and Jean Charles Soria
Cancer Discov March 1 2013 (3) (3) 264-279; DOI: 10.1158/2159-8290.CD-12-0362
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • FGFs and FGFRs in Human Physiology
    • FGF Signaling and Cancer Progression
    • Anti-FGFR Drugs: State of the Art
    • Challenges and Perspectives
    • Conclusions
    • Disclosure of Potential Conflicts of Interest
    • Authors' Contributions
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Modes of Regulated Cell Death in Cancer
  • Necroptosis, Pyroptosis, and Antitumor Immunity
  • Drug Development for Pediatric Cancer
Show more Review
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • OnlineFirst
  • Current Issue
  • Past Issues

Info For

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Discovery

  • About the Journal
  • Editors
  • Journal Sections
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Discovery
eISSN: 2159-8290
ISSN: 2159-8274

Advertisement